LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS. (June 2017) - Kolstad, A.